1,720,990 research outputs found
Using cure modelling for cost effectiveness in the NICE technology appraisal of Polatuzumab Vedotin in combination for untreated diffuse large B cell lymphoma: an external assessment group perspective
No full textPolatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma: a single technology appraisal
No full textThis report is a critique of the company’s submission (CS) to NICE from Roche on the clinical effectiveness and cost effectiveness of polatuzumab [POLIVY®] for treating adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). It identifies the strengths and weaknesses of the CS
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]: a single technology appraisal
No full textThis report is a critique of the company’s submission (CS) to NICE from Astellas Pharma Ltd on the clinical effectiveness and cost effectiveness of enfortumab vedotin with pembrolizumab for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. It identifies the strengths and weaknesses of the CS
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]: a single technology appraisal
No full textThis report is a critique of the company’s submission (CS) to NICE from Menarini Stemline UK Ltd on the clinical effectiveness and cost effectiveness of elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1mutation after at least one endocrine treatment. It identifies the strengths and weakness of the CS. Clinical experts were consulted to advise the external assessment group (EAG) and to help inform this report
Relugolix for treating hormone-sensitive prostate cancer: a single technology appraisal
No full textThis report is a critique of the company’s submission (CS) to NICE from Accord Healthcare on the clinical effectiveness and cost effectiveness of relugolix for treating treating hormone sensitive prostate cancer. It identifies the strengths and weakness of the CS
Mirikizumab for treating moderately to severely active ulcerative colitis: a single technology appraisal
No full textThe company (Eli Lilly) submitted evidence to NICE for mirikizumab, in the treatment of people with moderately to severely active ulcerative colitis (UC), to be considered under NICE’s proportionate approach to technology appraisals (PATT) streamlined cost-comparison process. This report is the external assessment group’s (EAG’s) critique of the company’s submission (CS). It identifies the strengths and weaknesses of the CS
An economic evaluation of local anaesthetic transperineal biopsy in people with suspected prostate cancer
No full textHealth care professional barriers and facilitators to discontinuing antidepressant use: A systematic review and thematic synthesis
No full textIntroduction: long-term antidepressant (AD) use, much longer than recommended, is very common and can lead to potential harms.Objective: to investigate the existing literature on perspectives of health professionals (HPs) regarding long-term AD treatment, focusing on barriers and facilitators to discontinuation.Methods: a systematic review with thematic synthesis. Eight electronic databases were searched until August 2023 including MEDLINE, PubMed, Embase, PsycINFO, CINAHL, AMED, Health Management Information Consortium, and the Networked Digital Library of Theses and Dissertation.Results: thirteen studies were included in the review. Of these, nine focused on general practitioner perspectives, one on psychiatrist perspectives, and three on a mix of HPs perspectives. Barriers and facilitators to discontinuing long-term ADs emerged within eight themes, ordered chronologically based on HP considerations during an AD review: perception of AD use, fears, HP role and responsibility, HPs' perception of AD discontinuation, HPs' confidence regarding their ability to manage discontinuation, perceived patient readiness to stop, support from patient's trusted people, and support from other HPs.Limitations: coding and development of subthemes and themes was performed by one researcher and further developed through discussion within the research team.Conclusion: deprescribing long-term ADs is a challenging concept for HPs. The review found evidence that the barriers far outweigh the facilitators with fear of relapse as a main barrier. HP education, reassurance and confidence-building is essential to increase the initiation of the discontinuation process. Further research into the perspectives of pharmacists and mental health workers is needed as well as exploring the role of trusted people
Daratumumab in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (review of TA573): a single technology appraisal
No full textIn this report we provide a critique of the CDF review company’s submission (CS) to NICE for the review of TA5731 on the clinical effectiveness and cost effectiveness of daratumumab with bortezomib and dexamethasone (DBd) for treating relapsed or refractory multiple myeloma following the period of managed access within the Cancer Drugs Fund (CDF)
- …
